Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 7—July 2014
Letter

Carbapenemase-producing Bacteria in Patients Hospitalized Abroad, France

Fabrice Compain, Dominique Decré, Isabelle Frazier, Astrid Ramahefasolo, Marie Lavollay, Etienne Carbonnelle, Hidayeth Rostane, Arzu Tackin, Anne Berger-Carbonne, and Isabelle PodglajenComments to Author 
Author affiliations: Hôpital Européen Georges Pompidou, AP-HP, Paris, France (F. Compain, I. Frazier, A. Ramahefasolo, M. Lavollay, E. Carbonnelle, H. Rostane, A. Tackin, A. Berger-Carbonne, I. Podglajen); Université Pierre et Marie Curie, Paris (D. Decré); Université Paris Descartes, Paris (M. Lavollay, E. Carbonnelle, I. Podglajen); Collège de France, Centre de Recherche Interdisciplinaire en Biologie, Paris (I. Podglajen); Institut National de la Santé et de la Recherche Médicale, Paris (M. Lavollay, E. Carbonnelle, I. Podglajen)

Main Article

Table

Clinical and laboratory data on 33 patients hospitalized in France who were previously hospitalized in other countries and were carrying carbapenemase-producing bacteria, glycopeptide-resistant enterococci, or both*

Patient no.
 Year of initial hospital admission
 Patient transfer status
 Country of hospitalization
 Species of infection
 β-lactamase content Glycopeptide resistance gene
ESBL
 Carbapenemase
1† 2010 DT Egypt E. coli Pos OXA-48
2† 2010 DT Thailand A. baumannii Pos OXA-23
3† 2010 DT Iraq A. baumannii Neg OXA-23
E. faecium vanA‡
4 2010 NDT USA E. faecium vanA
5 2011 NDT Morocco K. pneumoniae Neg OXA-48
K. pneumoniae Neg OXA-48
6† 2011 DT Senegal K. pneumoniae Pos OXA-48
7 2011 DT Congo E. faecium vanA‡
8† 2011 NDT Benin A. baumannii Neg OXA-23‡
9 2011 NDT Kuwait P. aeruginosa Neg VIM-2
10† 2011 NDT Kuwait K. pneumoniae Neg OXA-48
11† 2011 NDT Kuwait P. aeruginosa Neg VIM-2
12† 2011 NDT Kuwait E. faecium vanA
13† 2011 DT Libya K. pneumoniae Pos OXA-48
14† 2011 DT Libya E. coli Pos OXA-48
K. pneumoniae Pos OXA-48
A. baumannii Neg OXA-23
E. faecium vanA
15 2011 NDT Saudi Arabia E. faecium vanA
16† 2011 NDT Pakistan E. faecium vanA
17 2011 NDT Italy A. baumannii Neg OXA-23
K. pneumoniae Neg KPC-3
18† 2011 DT Spain K. pneumoniae Neg OXA-48
19 2011 NDT Israel K. pneumoniae Neg KPC-3
20† 2012 DT Egypt A. baumannii Neg NDM-1
A. baumannii Neg NDM-1
P. putida Neg VIM-2
21† 2012 DT Tunisia E. coli Pos OXA-48
K. pneumoniae Pos OXA-48
K. pneumoniae Neg OXA-48
22† 2012 NDT Tunisia A. baumannii Neg OXA-23
23† 2012 DT India E. coli Neg NDM-1
M. morgannii Pos NDM-1
P. aeruginosa Neg VIM-2
24† 2012 NDT Cambodia E. coli Neg NDM-4‡
E. coli Pos OXA-48‡
25† 2012 DT Sri Lanka E. coli Pos OXA-48‡
K. pneumoniae Pos OXA-181‡
26 2013 NDT Algeria E. coli Neg OXA-48
27† 2013 NDT Algeria E. coli Neg OXA-48
28 2013 DT Tunisia A. baumannii Neg NDM-1
29† 2013 DT Libya K. pneumoniae Pos OXA-48
30 2013 DT Libya K. pneumoniae Pos OXA-48
K. pneumoniae Pos OXA-48
31 2013 NDT India E. coli Pos OXA-181
E. coli Neg NDM-7‡
K. pneumoniae Neg NDM-7‡
32 2013 NDT Georgia P. aeruginosa Pos VIM-2‡
33† 2013 DT Montenegro E. faecium vanA‡

*ESBL, extended-spectrum β-lactamase; DT, direct transfer from hospital abroad to HEGP; E. coli, Echerichia coli; Pos, positive; A. baumannii, Acinetobacter baumannii; Neg, negative; E. faecium, Enterococcus faecium; NDT, nondirect transfer (hospitalized abroad within 12 mo before transfer to HEGP); K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa; Pseudomonas aeruginosa; P. putida, Pseudomonas putida; M. morganii, Morganella morganii.
†Patient carrying an ESBL producer in addition to the carbapenemase-producing bacteria and/or glycopeptide-resistant enterococci.
‡Resistance gene not reported previously in the country of initial hospitalization.

Main Article

Page created: June 18, 2014
Page updated: June 18, 2014
Page reviewed: June 18, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external